Pelusi C, Fanelli F, Baccini M, et al. - In this ancillary study of a cross-over, randomized, double-blind, placebo-controlled trial, researchers analyzed Sertoli cell (SC) function by evaluating Inhibin B (IB) and Anti-Mullerian Hormone (AMH) levels at baseline and after 3 month of clomiphene citrate (CC) treatment to assess androgen response to CC treatment in dysmetabolic obese individuals with low T levels treated with metformin. After each treatment period, no significant changes were noted for IB and AMH concentrations; whereas T and estradiol (E2) levels in the CC plus metformin (CC/Met) phase alone were shown to be significantly higher. In comparison to LC activity, CC was unable to affect SC function, as evidenced by the lack of IB and AMH serum modifications, indicating an intrinsic non-reversible SC cell defect in patients with dysmetabolic conditions.